Drug Utilization Review Board
Meeting Agenda
Thursday, December 11, 2025
7:15 a.m. to 8:30 a.m.
Google Meet joining info
Video call link: meet.google.com/zue-rrqz-rpb
Or dial: (US) +1 904-900-0180 PIN: 172 873 306#
Persons who wish to address the DUR Board may contact Luis Moreno at lmoreno@utah.gov prior to the meeting, or sign up to provide comments at the meeting. Public comments will be limited to 3 minutes per speaker or organization due to time constraints.
1) Call to order - Sharon Weinstein, MD
a) Welcome and Introductions
b) Review and Approval of Minutes
2) Prior Authorization Updates - Luis Moreno, PharmD
3) P&T Committee Update - Luis Moreno, PharmD
4) Public Comment
5) Review New Prior Authorization Criteria
a) Opzelura (ruxolitinib cream) - Luis Moreno, PharmD
i) Committee Discussion/Questions
ii) Committee Action
b) Rinvoq, Rinvoq LQ (upadacitinib) - Luis Moreno, PharmD
i) Committee Discussion/Questions
ii) Committee Action
c) Tyenne (tocilizumab-aazg) and Biosimilars - Kyu Yun Park, PharmD
i) Committee Discussion/Questions
ii) Committee Action
d) Xeljanz, Xeljanz XR (tofacitinib) - Kyu Yun Park, PharmD
i) Committee Discussion/Questions
ii) Committee Action
e) Wegovy for the Treatment of MASH - Iris Wan, PharmD
i) Committee Discussion/Questions
ii) Committee Action
f) Airsupra (albuterol and budesonide) - Skylar Fenton, PharmD
i) Committee Discussion/Questions
ii) Committee Action
6) Next Meeting
a) Date: January 8, 2025
b) Topic: Combination Treatment with Botox and a Calcitonin Gene-Related Peptide Antagonist in the Setting of Chronic Migraine
7) Adjourned - Sharon Weinstein, MD
Notice of Special Accommodations (ADA)
In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Luis Moreno at 801-538-6155.
Notice of Electronic or Telephone Participation
Video call link: meet.google.com/zue-rrqz-rpb
Or dial: (US) +1 904-900-0180 PIN: 172 873 306#